Warner Pharmaceuticals: Ferrous Succinate Tablets and Sodium Diclofenac Sustained Release Tablets are planned to be selected for centralized procurement.

Warner Pharmaceuticals announced that on July 31, 2026, the company participated in the twelfth batch of national centralized drug procurement bidding, with Ferrous Succinate Tablets and Sustained-Release Diclofenac Sodium Tablets expected to be selected. The sales revenue for Ferrous Succinate Tablets in 2025 and the first quarter of 2026 were 89.455 million yuan and 19.062 million yuan, respectively; the same for Sustained-Release Diclofenac Sodium Tablets were 89.3605 million yuan and 20.1963 million yuan for the same periods. The proposed selection price represents a decrease from the original selling price. If the procurement contract is subsequently signed and executed, it will be beneficial for expanding product channels, broadening market reach, and enhancing brand influence. However, there are uncertainties regarding the signing of the procurement contract and other follow-up matters.